Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The price of KalVista Pharmaceuticals Inc (NASDAQ: KALV) closed at $13.34 in the last session, up 3.57% from day before closing price of $12.88. In other words, the price has increased by $3.57 from its previous closing price. On the day, 1.0 million shares were traded. KALV stock price reached its highest trading level at $13.515 during the session, while it also had its lowest trading level at $12.81.
Ratios:
We take a closer look at KALV’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 5.35 and its Current Ratio is at 5.35. In the meantime, Its Debt-to-Equity ratio is 1.18 whereas as Long-Term Debt/Eq ratio is at 1.16.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JMP Securities on January 31, 2025, initiated with a Mkt Outperform rating and assigned the stock a target price of $19.
On January 07, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $30.
On December 18, 2024, BofA Securities started tracking the stock assigning a Buy rating and target price of $22.BofA Securities initiated its Buy rating on December 18, 2024, with a $22 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jul 09 ’25 when Palleiko Benjamin L sold 32,979 shares for $15.69 per share. The transaction valued at 517,523 led to the insider holds 369,595 shares of the business.
Yea Christopher sold 30,250 shares of KALV for $474,698 on Jul 09 ’25. The CHIEF DEVELOPMENT OFFICER now owns 127,939 shares after completing the transaction at $15.69 per share. On Jun 09 ’25, another insider, Palleiko Benjamin L, who serves as the CHIEF EXECUTIVE OFFICER of the company, sold 7,169 shares for $14.50 each. As a result, the insider received 103,950 and left with 315,074 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KALV now has a Market Capitalization of 666382336 and an Enterprise Value of 557954880.
Stock Price History:
The Beta on a monthly basis for KALV is -0.10, which has changed by 0.06592095 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, KALV has reached a high of $16.32, while it has fallen to a 52-week low of $7.30. The 50-Day Moving Average of the stock is -1.45%, while the 200-Day Moving Average is calculated to be 17.41%.
Shares Statistics:
According to the various share statistics, KALV traded on average about 1.20M shares per day over the past 3-months and 694000 shares per day over the past 10 days. A total of 49.76M shares are outstanding, with a floating share count of 37.31M. Insiders hold about 22.43% of the company’s shares, while institutions hold 87.50% stake in the company. Shares short for KALV as of 1753920000 were 10055796 with a Short Ratio of 8.41, compared to 1751241600 on 8499323. Therefore, it implies a Short% of Shares Outstanding of 10055796 and a Short% of Float of 22.709998000000002.
Earnings Estimates
At present, 8.0 analysts are actively evaluating the performance of KalVista Pharmaceuticals Inc (KALV) in the stock market.The consensus estimate for the next quarter is -$0.9, with high estimates of -$0.75 and low estimates of -$1.0.
Analysts are recommending an EPS of between -$2.81 and -$3.71 for the fiscal current year, implying an average EPS of -$3.31. EPS for the following year is -$2.17, with 7.0 analysts recommending between -$1.7 and -$2.78.
Revenue Estimates
Based on 7 analysts’ estimates, the company’s revenue will be $116.93M in the next fiscal year. The high estimate is $150M and the low estimate is $87.27M.
